Abemaciclib - CAS 1231929-97-7
Catalog number:
1231929-97-7
Category:
Inhibitor
Not Intended for Therapeutic Use. For research use only.
COA:
Inquire
Targets:
CDK
Description:
Abemaciclib is orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity.
Publictions citing BOC Sciences Products
  • >> More
Synonyms:
LY-2835219; LY 2835219
MSDS:
Inquire
Current Developer:
Eli Lilly
1.Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
Tate SC1, Burke TF2, Hartman D2, Kulanthaivel P2, Beckmann RP2, Cronier DM1. Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.
BACKGROUND: Resistance to BRAF inhibition is a major cause of treatment failure for BRAF-mutated metastatic melanoma patients. Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, overcomes this resistance in xenograft tumours and offers a promising drug combination. The present work aims to characterise the quantitative pharmacology of the abemaciclib/vemurafenib combination using a semimechanistic pharmacokinetic/pharmacodynamic modelling approach and to identify an optimum dosing regimen for potential clinical evaluation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related CDK Products


CAS 1204918-72-8 SB1317

SB1317
(CAS: 1204918-72-8)

SB1317 is a novel small molecule potent CDK/JAK2/FLT3 inhibitor. It dose-dependently inhibits signaling pathways downstream of CDKs, JAK2 and FLT3 in cancer cel...

CAS 802539-81-7 Milciclib

Milciclib
(CAS: 802539-81-7)

Milciclib is an orally bioavailable inhibitor of cyclin-dependent kinases (CDKs) and thropomyosin receptor kinase A (TRKA), with potential antineoplastic activi...

CAS 186692-46-6 Seliciclib

Seliciclib
(CAS: 186692-46-6)

Seliciclib is an orally bioavailable, small-molecule cyclin-dependent kinase (CDK) inhibitor with potential proapoptotic and antineoplastic activities. Selicicl...

CAS 211555-08-7 WHI-P180

WHI-P180
(CAS: 211555-08-7)

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...

CAS 1211443-80-9 LEE011 hydrochloride

LEE011 hydrochloride
(CAS: 1211443-80-9)

CDK4/6 inhibitor LEE011 specifically inhibits CDK4 and 6, thereby inhibiting retinoblastoma (Rb) protein phosphorylation. Inhibition of Rb phosphorylation preve...

CAS 582315-72-8 BMS-265246

BMS-265246
(CAS: 582315-72-8)

BMS-265246 is a potent and selective CDK1/2 inhibitor with IC50 of 6 nM/9 nM. It is 25-fold more selective for CDK1/2 than CDK4.

CAS 1604810-83-4 THZ1

THZ1
(CAS: 1604810-83-4)

THZ1 is a selective CDK7 inhibitor that preferentially diminishes transcription in cancer cells. THZ1 has the unprecedented ability to target a remote cysteine ...

CAS 1397219-81-6 BS-181 HCl

BS-181 HCl
(CAS: 1397219-81-6)

BS-181 HCl is a highly selective CDK7 inhibitor with IC50 of 21 nM. It is more than 40-fold selective for CDK7 than CDK1, 2, 4, 5, 6, or 9.

CAS 153437-55-9 WHI-P180 hydrochloride

WHI-P180 hydrochloride
(CAS: 153437-55-9)

WHI-P180 moderately inhibited ABCG2 function, exhibiting weak phototoxicity. The elimination half-life of WHI-P180 in CD-1 mice (BALB/ c mice) following i.v., i...

CAS 189232-42-6 Bohemine

Bohemine
(CAS: 189232-42-6)

Bohemine, structurally similar to Olomoucine and Roscovitine, is a 2,6,9-trisubstituted purine derivative that inhibits cyclin-dependent kinases (CDKs) and exhi...

CAS 902156-99-4 NVP-LCQ195

NVP-LCQ195
(CAS: 902156-99-4)

NVP-LCQ195 is a small molecule heterocyclic inhibitor of CDK1, CDK2, CDK3 and CDK5. It induced cell cycle arrest and eventual apoptotic cell death of MM cells, ...

CAS 345627-80-7 SNS-032

SNS-032
(CAS: 345627-80-7)

SNS-032, also known as BMS-387032, is a 2-aminothiazole-derived, small-molecule cyclin dependent kinase (CDK) inhibitor with potential antineoplastic activity. ...

CAS 902135-91-5 AT7519 HCl

AT7519 HCl
(CAS: 902135-91-5)

CAS 377090-84-1 SU9516

SU9516
(CAS: 377090-84-1)

SU 9516 is a potent, selective cdk2 inhibitor (IC50 values are 0.022, 0.04, >10, >10, 18 and >100 μM for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively...

AU-12122

AU-12122 is a novel-developed CDK7 inhibitor, which is potent and orally bioactive. It induces apoptosis of acute monocytic leukemia THP-1.

CAS 1374639-75-4 LEE011 succinate

LEE011 succinate
(CAS: 1374639-75-4)

LEE011 is an orally bioavailable and highly specific CDK4/6 (cyclin-dependent kinase 4/6) inhibitor. LEE011 in combination with LGX818 (a V600E BRAF specific in...

CAS 1092443-52-1 BS181

BS181
(CAS: 1092443-52-1)

BS-181 is a highly selective CDK inhibitor for CDK7 with an IC(50) of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inh...

CAS 212844-54-7 Purvalanol B

Purvalanol B
(CAS: 212844-54-7)

Purvalanol B is a cyclin-dependent; 2,6,9-substituted kinase inhibitor.

THZ1-R
(CAS: 1621523-07-6)

THZ1-R, with the potential to treat Triple-negative breast cancer (TNBC), it is a potent and selective CDK7 inhibitor but has instability in vivo.

CAS 1263369-28-3 CDK9-IN-2

CDK9-IN-2
(CAS: 1263369-28-3)

CDK9-IN-2 is a novel cyclin-dependent kinase 9(CDK9) inhibitor.

Chemical Structure

CAS 1231929-97-7 Abemaciclib

Quick Inquiry

Verification code

Featured Items